Kazakov Y. M., Chekalina N. I., Plaksa V. M.

LITERATURE REVIEWS

Scentific article

Introduction. Chronic heart failure (CHF) is one of the leading causes of disability and mortality in the population, with a high prevalence in the world and an unrelenting rate of increase in morbidity. Recently, there has been an increasing prevalence of CHF in women, in old age, compared to men, its prevalence becomes three times greater. In postmenopause, the frequency of arterial hypertension (AH), coronary heart disease, which creates conditions for the development of CHF, increases significantly. Therefore, it is relevant to study the characteristics of CHF on the background of hypertension in postmenopausal women with the aim of timely diagnosis and treatment in the initial stages. The purpose of the work is an analytical study with the determination of the leading pathogenetic mechanisms of the formation of CHF against the background of hypertension in postmenopausal women. Main part. The review presents the main ideas about pathogenetic mechanisms of CHF development and progression. The role of neuro-humoral activation, hemodynamic overload in conditions of hypertension, violation of the metabolism of the extracellular matrix with the formation of myocardial stiffness is indicated. The main attention is paid to the new concept of the development of CHF, which consists in the influence of immune activation and systemic inflammation. The role of pro-inflammatory cytokines in the development of endothelial dysfunction, remodeling of the myocardium and the progression of CHF is noted. An independent factor of pathogenetic changes in the development of CHF is hypoestrogeny in postmenopause. Mechanisms of activation of pressor systems in conditions of estrogen deficiency and mediated effects are presented, including molecular mechanisms of connective tissue dysmetabolism, cardiohemodynamic consequences and their interrelationship. Common links were found in the pathogenesis of hypertension, CHF and processes accompanying postmenopause. The pro-inflammatory signaling cascades involved and activated in the mechanisms of CHF formation in postmenopausal women, in particular, with the participation of interleukin ST2, osteoprotegerin, are described in detail. The importance of hypoestrogenia in the activation of pro-inflammatory mechanisms with the development of osteodysmetabolism, myocardial fibrosis and remodeling and their relationship through the prism of systemic inflammation is substantiated. Potential early markers of the development of CHF are presented, and possible directions of therapeutic influence are indicated. Conclusions. The review systematizes modern ideas about the pathogenetic mechanisms of the development of CHF in postmenopausal women against the background of hypertension, which determines the prospects for solving the problematic issues of diagnosis and treatment of CHF.

chronic heart failure,arterial hypertension,postmenopause,pathogenetic mechanisms.

1. Kovalenko VM, Lutai MI, Sirenko YuM, Sychov OS. Sertsevo-sudynni zakhvoriuvannia: klasyfikatsiia, standarty diahnostyky ta likuvannia. Kiev: Morion; 2019. 239 s. [in Ukrainian].
2. Di Cesare E, Carerj S, Palmisano A, Carerj ML, Catapano F, Vignale D, et al. Multimodality imaging in chronic heart failure. Radiol. Med. 2021 Jul 16;126(2):231-242.
3. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the american college of cardiology. Circulation. 2013 Jun 24;129(25):49-73.
4. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133.
5. Fang N, Jiang M, Fan Y. Ideal cardiovascular health metrics and risk of cardiovascular disease or mortality: a meta-analysis. Int J Cardiol. 2016 Jul 1;214:279-83.
6. Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail. 2020 Jul;8(7):523- 536.
7. Voronkov LH. Patsiient iz KhSN v Ukraini: analiz usiiei populiatsii patsiientiv, obstezhenykh u ramkakh pershoho natsionalnoho zrizovoho doslidzhennia UNIVERS. Sertseva nedostatnist. 2012;1:8-14. [in Ukrainian].
8. Kovalenko VM, Dorohoi AP. Sertsevo-sudynni khvoroby: medychno-sotsialne znachennia ta stratehiia rozvytku kardiolohii v Ukraini. Ukr kardiol zhurn. 2016;3:5-14. [in Ukrainian].
9. Drozdova IV, Matsuha OM, Babets AA. Pervynna invalidnist unaslidok hipertonichnoi khvoroby ta tserebrovaskuliarnykh zakhvoriuvan: pidkhody do analizu ta prohnozuvannia. Ukrainskyi visnyk medyko-sotsialnoi ekspertyzy. 2016;1:14-21. [in Ukrainian].
10. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan;8(1):30-41.
11. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017 Oct;14(10):591- 602.
12. Podzolkov VY, Mozharova LH, Khomytskaia YuV. Arteryalnaia hypertenzyia u zhenshchyn s klymakterycheskym syndromom. Obzory klynycheskoi kardyolohyy. 2015;1:5-10.
13. Kovalenko VM, Kornatskyi VM, Manoilenko T, Dorokhina A, Tsyzh O, Revenko I, et al. Stan zdorovia narodu Ukrainy ta medychnoi dopomohy tretynnoho rivnia: posibnyk. Kyiv: SI NSC Institute of Cardiology named after Acad. MD Strazhesko; 2019. 222 s. [in Ukrainian].
14. Sirenko Yu M. Medyko-sotsialni problemy kardiolohichnoi dopomohy v Ukraini: shliakhy vyrishenni. Problemy bezperervnoi medychnoi osvity ta nauky. 2014;2:6-10. [in Ukrainian].
15. Kovalenko VN, Svyshchenko EP. Lechenye arteryalnoi hypertenzyy v osobыkh klynycheskykh sytuatsyiakh. Kamenets-Podolskyi: Ynstytut kardyolohyy; 2005. 501 s.
16. Regnault V, Lacolley P, Safar ME. Hypertension in postmenopausal women: hemodynamic and therapeutic implications. J Am Soc Hypertens. 2018;12(3):151-153.
17. Srivaratharajah K, Abramson BL. Hypertension in menopausal women: the effect and role of estrogen. Menopause. 2019 Apr;26(4):428- 430.
18. Kim JM, Kim TH, Lee HH, Lee SH, Wang T. Postmenopausal hypertension and sodium sensitivity. J Menopausal Med. 2014 Apr; 20(1):1-6.
19. Voronkov LH. Patsiient iz KhSN v Ukraini: analiz danykh populiatsii patsiientiv, obstezhenykh u ramkakh pershoho natsionalnoho zrizovoho doslidzhennia UNIVERS. Sertseva nedostatnist. 2016;1(1):8-13. [in Ukrainian].
20. Pashkova I, Zhebel V, Palahniuk H, Antoniyk Y, Syvak V. Spadkovi chynnyky v rehuliatsii arterialnoho tysku, yak chynnyk rozvytku khronichnoi sertsevoi nedostatnosti na tli hipertonichnoi khvoroby: novi realii ta perspektyvy. Praktykuiuchyi likar. 2018;1:16-20. [in Ukrainian].
21. Vasiuk YuA, Dudarenko OP, Yushchuk EN, Shkolnyk EL, Serova MK. «Tsytokynovaia» model patoheneza khronycheskoi serdechnoi nedostatochnosty y vozmozhnosty novoho terapevtycheskoho podkhoda v lechenyy dekompensyrovannykh bolnykh. Ratsyonalnaia farmakoterapyia v kardyolohyy. 2006;2(4):63-70. [in Ukrainian].
22. DeLeon-Pennell KY, Jung M, Ma Y, Iyer RP, Yabluchanskiy A, Garrett MR, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol. 2017 May;112(3):33.
23. Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis. The heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021 May 14;128(10):1451-1467.
24. Kaliuzhyn VV, Tepliakov AT, Vecherskyi YuIu, Riazantseva NV, Khlapov AP. Patohenez khronycheskoi serdechnoi nedostatochnosty: yzmenenye domynyruiushchei paradyhmы. Biulleten sybyrskoi medytsyni. 2007;6(4):71-79.
25. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. J Am Coll Cardiol HF. 2016 Apr;4(4):312-324.
26. Vizir VA, Berezin OE, Demidenko OV. Perspektyvy vidnovlennia funktsii endoteliiu pry arterialnii hipertenzii. Liky. 2000;3-4:5-12. [in Ukrainian].
27. González A, Fortuño MA, Querejeta R, Ravassa S, López B, López N, et.al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res. 2003 Sept; 59(3):549-62.
28. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: A Review. JAMA. 2020 Aug 4;324(5):488-504.
29. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. The Lancet. 2011 Aug; 378:704-12.
30. Iorga A, Umar S, Ruffenach G, Aryan L, Li J, Sharma S, et al. Estrogen rescues heart failure through estrogen receptor Beta activation. Biol Sex Differ. 2018 Oct;9(1):48.
31. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005 Feb;111(7):871-8.
32. Terrovitis J, Zotos P, Kaldara E, Diakos N, Tseliou E, Vakrou S, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012 Mar;14(3):326-332.
33. Smetnyk VP, Shestakova YH. Sovremennye predstavlenyia o menopauzalnom metabolycheskom syndrome. Consilium medicum. 2003;5(9):543-6.
34. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998 Jan 3;351(9095):9-13.
35. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013 Dec;18(12):15314-28.
36. Kopeva KV, Tepliakov AT, Tarasov NY, Ysakov LK, Hrakova EV, Synkova MN, et al. Prohnoz serdechno-sosudystыkh sobыtyi posle ymplantatsyy kardyovertera-defybrylliatora patsyentam s khronycheskoi serdechnoi nedostatochnostiu: znachenye povyshenyia kontsentratsyy endotelyna-1 y rastvorymoi formy belka ST2 v plazme krovy. Biulleten sybyrskoi medytsyni. 2018;17(3):140-150.
37. Memon AA, Sundquist K, Pirouzi Fard M, Elf JL, Strandberg K, Svensson PJ, et al. Identification of novel diagnostic biomarkers for deep venous thrombosis. Br J Haematol. 2018 May;181(3):378-85.
38. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. International journal of cardiology. 2014;172(1):250-52.
39. Nadar SK, Shaikh MM. Biomarkers in routine heart failure clinical care. Card Fail Rev. 2019 Feb;5(1):50-56.
40. Shah RV, Januzzi JL Jr. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010 Mar;7(1):9-14.
41. Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol. 2015 Apr;184:337-43.
42. Aimo A, Januzzi JL Jr, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J Am Coll Cardio. 2019 Oct;74(17):2193-2203.
43. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001 Jul;164(2):277-281.
44. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001 Jun;284(5):1104-1108.
45. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocrine reviews. 2008 Apr;29(2):155-192.
46. Trouvin AP, Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345. DOI: 10.2147/CIA.S10153.
47. Kaidashev YP. Aktyvatsyia yadernoho faktora κB kak molekuliarnoi osnovi patoheneza metabolycheskoho syndroma. Patolohycheskaia fyzyolohyia y eksperymentalnaia terapyia. 2013;3:65-72.
48. Lorenz H, Rachner T. Die Rolle des RANK/RANKL/OPG-Signalwegs im Knochenstoffwechsel. Fortbildung Osteologie. 2010;3:118-121.
49. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005 Nov;20(11):1912-20.
50. Özkalaycı F, Gülmez Ö, Uğur-Altun B, Pandi-Perumal SR, Altun A. The role of osteoprotegerin as a cardioprotective versus reactive inflammatory marker: the chicken or the egg paradox. Balkan Med J. 2018 May 29;35(3):225-232.
51. Bhupathy P, Haines CD, Leinwand LA. Influence of sex hormones and phytoestrogens on heart disease in men and women. Women’s health. 2010 Jan;6(1):77-95.
52. Lyskova YuV, Stadnykov AA, Salykova SP. Rol telotsytov v remodelyrovanyy myokarda y razvytyy serdechno-sosudystykh oslozhnenyi u patsyentov s khronycheskoi serdechnoi nedostatochnostiu posle koronarnoho shuntyrovanyia. Kardyolohyia. 2018;58(8):29-37.
53. Pomatto LCD, Davies KJA. Adaptive homeostasis and the free radical theory of ageing. Free Radic Biol Med. 2018 Aug;124:420-430.
54. Shostak NA, Pravdyuk NG, Anichkov DA, Kondrashov AA. Hypertension in postmenopausal women: possibilities of combination therapy. The Clinician. 2013;7(3-4):80-86.
55. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metabolism. 2012 May; 15(5):675-690.
56. Torre E. Molecular signaling mechanisms behind polyphenol-induced bone anabolism. Phytochem Rev. 2017;16(6):1183-1226.
57. Nicolin V, De Tommasi N, Nori SL, Costantinides F, Berton F, Di Lenarda R. Modulatory effects of plant polyphenols on bone remodeling: a prospective view from the bench to bedside. Frontiers in Endocrinology. 2019 Jul;10:494.
58. Zakłos-Szyda M, Budryn G, Grzelczyk J, Pérez-Sánchez H, Żyżelewicz D. Evaluation of isoflavones as bone resorption inhibitors upon interactions with receptor activator of nuclear factor-κB ligand (RANKL). Molecules. 2020 Jan;25(1):206.
59. Cebova M, Pechanova O. Protective effects of polyphenols against ischemia/reperfusion injury. Molecules. 2020 Jul;25(15):3469.
60. Kaidashev YP. Syrtuyni–unyversalnie rehuliatori kletochnikh funktsyi. Вiopolymers and Cell. 2012;28(2):93-102.
61. Chekalina N, Burmak Y, Petrov Y, Borisova Z, Manusha Y, Kazakov Y, et al. Quercetin reduces the transcriptional activity of NF-kB in stable coronary artery disease. Indian Heart J. 2018;70(5):593-97.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 45-50 pages, index UDK 618.173-021.68-06:616.12-008.331.1:616.12-008.46-02

10.29254/2077-4214-2022-3-166-45-50